Skip to main content
. 2020 Jul 29;6(31):eaba0466. doi: 10.1126/sciadv.aba0466

Fig. 5. R13 administration blunts C/EBPβ/AEP signaling in the gut of 5xFAD mice.

Fig. 5

(A) Immunoblot showing p-C/EBPβ, C/EBPβ, AEP, APP, and Tau expression and processing in the mouse colon. (B) IF staining of C/EBPβ. Scale bar, 20 μm. (C to G) IF staining of AEP and Aβ in colon of 5xFAD mice and the quantification. Scale bars, 200 μm. (H) AEP activity assay of the colon lysates from 5xFAD treated with antibiotics or vehicle. Data represent the means ± SEM; representative data of six samples; *P < 0.05 compared with control, one-way ANOVA. (I) GI permeability barrier defect as determined by FITC-dextran translocation in R13-treated 5xFAD mice and vehicle mice. Data represent the means ± SEM; representative data of four samples; *P < 0.05, **P < 0.01, and ***P < 0.001 compared with control, one-way ANOVA. (J) R13 treatment decreased IL-6 but not TNF-α or IL-1β expression. Data represent the means ± SEM; representative data of four samples; ***P < 0.001 compared with control, one-way ANOVA.